Page 15 - ஜூ இ News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஜூ இ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஜூ இ Today - Breaking & Trending Today
困境中求生的旅游从业者:开直播、搞副业 坚信春天一定会来 ——凤凰网房产天津 ifeng.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ifeng.com Daily Mail and Mail on Sunday newspapers.
困境中求生的旅游从业者:开直播、搞副业,坚信春天一定会来 nbd.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nbd.com.cn Daily Mail and Mail on Sunday newspapers.
每经记者新春走基层| 困境中求生的旅游从业者:开直播、搞副业,坚信春天一定会来 nbd.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nbd.com.cn Daily Mail and Mail on Sunday newspapers.
留深过年当起志愿者,罗湖教育人用爱书写美好时光 oeeee.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oeeee.com Daily Mail and Mail on Sunday newspapers.
Share this article Share this article WALTHAM, Mass., Feb. 3, 2021 /PRNewswire/ Thermo Fisher Scientific, the world leader in serving science, has signed an agreement with JW Therapeutics, a leading cell therapy company, to ensure non-exclusive commercial access to Thermo Fisher s Gibco CTS Dynabeads CD3/CD28. The agreement will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW Therapeutics lead product relmacabtagene autoleucel ( relma-cel ). Relma-cel is an anti-CD19 CAR-T therapy for third-line treatment for relapsed or refractory ( r/r ) B-cell lymphoma. The therapy s new drug application (NDA) has been accepted by China s National Medical Products Administration (NMPA). Relma-cel is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China. ....